Select Committee on Biotechnology & Medical Technology
Assembly Committee on Privacy & Consumer Protection
Joint Informational Hearing
Tuesday, August 4, 2026
State Capitol, Room 126 - 10:00 a.m.

Panelist Biographies:

Dr. Ida Sim - Ida Sim, MD, PhD is Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley), Co-Director of the UCSF UC Berkeley Joint Program in Computational Precision Health, past Chief Research Informatics Officer for UCSF, and is a practicing primary care physician. Her research focuses on large-scale scientific computing infrastructures and policies for large-scale data sharing of health data. She co-leads JupyterHealth, an open platform for AI and digital health for prevention to chronic complex care. She has co-founded two non-profits: Open mHealth, which creates data standards for health sensor data, and Vivli, the world's largest data sharing platform for participant-level clinical trial data. In prior work, Dr. Sim was the founding Project Coordinator of the World Health Organization's International Clinical Trials Registry Platform and led the establishment of the first global policy on clinical trial registration.

Dr. Karen E. Knudsen, MBA PhD, is an internationally recognized CEO, oncology leader, scientist, and healthcare executive with 30+ years of experience driving innovation across academic medicine, nonprofit leadership, and biotech. Known for uniting science, strategy, and policy to create meaningful change, she has dedicated her career to improving outcomes for cancer patients. She currently serves as CEO of the Parker Institute for Cancer Immunotherapy (PICI), leading a bold, entrepreneurial organization committed to accelerating the next generation of breakthrough cancer therapies. PICI backs high-risk, high-reward science and builds the infrastructure to move discoveries from lab to clinic to market. With a model that spans research, clinical acceleration, and company formation, PICI has launched 17 biotech ventures that have raised over $4B to target some of the most difficult cancers. Dr. Knudsen serves on the Board of Directors for AstraZeneca, where she is a member of both the Science and Sustainability Committees, contributing to global R&D strategy and responsible corporate leadership. She is also a Board Director for Paradigm Health, Network Bio, and 3T Biosciences, where she helps guide innovation, strategy, and mission impact across the healthcare and life sciences sectors.
In addition, she serves as a Strategic Advisor for Color Heath, CellCentric, and Transcarent, as a Board Advisor to ArteraAI, sits on the Scientific Review Board for Genentech, and provides strategic counsel to multiple NCI-designated cancer centers via their External Advisory Boards. She previously served as President of AACI, on the NCI Board of Scientific Advisors and Boards of AACR and Research!America. Dr. Knudsen is also the immediate past CEO of the American Cancer Society and ACS CAN, where she unified operations, expanded mission reach, increased revenue, and drove record-breaking investments in research and patient services. Prior to ACS, she was EVP of Oncology Services for Jefferson Health and Director of the Sidney Kimmel Cancer Center. Her work has been recognized by Forbes, CNBC, and numerous scientific and

medical associations. She is an active member of the CNBC CEO Council, Wall Street Journal CEO Council, and Milken Institute Executive Circle.

Dr. Shankar Sundaram - Shankar Sundaram serves as Deputy Principal Associate Director for Mission Engineering and Director of the Bioresilience Incubator at Lawrence Livermore National Laboratory (LLNL), where he leads efforts to harness AI and biotechnology to strengthen bioresilience and national preparedness. His work encompasses secure compute, trusted biological data resources, foundational AI capabilities, and public-private partnerships to accelerate pathogen detection and characterization, as well as the rapid design of medical countermeasures.

He returned to LLNL after serving as Special Assistant to the President and Senior Director for Global Health Security and Biodefense at the National Security Council during the Biden Administration. In that role, he advised senior officials on global health security and biodefense, including outbreak response, AI and biotechnology policy, and biosafety.

Previously at LLNL, as Director of the Center for Bioengineering, he led interdisciplinary research spanning engineering, computing, and biology, and held senior leadership roles advancing national biosecurity through scientific and technological innovation. Earlier in his career, he worked at Draper Laboratory and in the private sector on microfluidics, microfabrication, and computational multiphysics. Shankar holds a doctorate in Chemical Engineering from Pennsylvania State University and a bachelor's degree also in Chemical Engineering from the Indian Institute of Technology, Madras.

Vibor Gupta (CEO), Pangaea Data Based in South San Francisco, Pangaea Data uses AI to help healthcare organizations find untreated and under-treated patients by analyzing existing clinical records through guideline-based reasoning. Its PALLUX platform supports earlier detection, care-gap closure, and clinical decision-making across conditions such as cancer, COPD, CKD, rare diseases, and tumor board workflows.

Ginny Hu, Senior Director, Regulatory Affairs, Dexcom - Ginny leads the RA team for digital health regulatory affairs efforts for software based products and solutions at Dexcom, including US/OUS software, data platform, APIs and data product regulatory classification, registration/approval and sustaining. Ginny's RA team also manages partnerships and cybersecurity regulatory efforts. Her team continues to support all regulatory activities, including US/OUS regulatory pathway, breakthrough device designation, IDE, Q-subs and 510(k) submissions associated with Dexcom's New Market initiatives.

Danjuma Quarless, PhD, MBA (Senior Director) AI Innovation, Lilly Ventures, Eli Lilly Danjuma Quarless is Senior Director of AI Innovation at Lilly Ventures, the strategic venture arm of Eli Lilly, where he focuses on early-stage investing at the intersection of artificial intelligence and drug development. His career spans computational biology, corporate strategy, and venture investing in biopharma. He began as a computational biologist, leading analytics for major population genomics initiatives including the UK Biobank and Genomics Finland, before moving into early-stage biotech investing. Danjuma holds a PhD in Biomedical Sciences from

UC San Diego and an MBA from the Kellogg School of Management at Northwestern University. Lilly Ventures is based in San Diego.

James Diggans, Vice President for Policy and Biosecurity - Twist Bioscience
James Diggans is Vice President for Policy and Biosecurity for Twist Bioscience, a DNA synthesis company based outside of San Francisco. He holds a PhD in Computational Biology and Bioinformatics from George Mason University and has worked in target discovery, molecular diagnostic development and biodefense. At Twist, he created and leads the company's biosecurity program, is a key member of the company's government affairs and policy team and chairs the International Gene Synthesis Consortium, a trade industry organization dedicated to ensuring the safe and secure use of synthetic DNA technology worldwide.

Dr. David Magnus - Title: David Magnus, PhD, Thomas A. Raffin Professor of Medicine and Biomedical Ethics, Professor of Pediatrics, By courtesy Professor of Bioengineering, Associate Dean of Research, Director Emeritus, Laurie J. Girand Center for Biomedical Ethics, Stanford University
Bio: David Magnus, PhD is Thomas A. Raffin Professor of Medicine and Biomedical Ethics and Professor of Pediatrics and Medicine and by Courtesy of Bioengineering at Stanford University and an Associate Dean for Research. He is Director Emeritus of the Laurie J. Girand Center for Biomedical Ethics. He is currently the Co-Chair of the IRB for the NIH Precision Medicine Initiative ("All of Us"). He is the former President of the Association of Bioethics Program Directors, and is the Editor in Chief of the American Journal of Bioethics. He has published articles on a wide range of topics in bioethics, including research ethics, AI ethics, genetics, stem cell research, organ transplantation, end of life, and patient communication. He was a member of the Secretary of Agriculture's Advisory Committee on Biotechnology in the 21st Century and currently serves on the California Human Stem Cell Research Advisory Committee. He is the principal editor of a collection of essays entitled "Who Owns Life?" (2002) and his publications have appeared in New England Journal of Medicine, JAMA, Science, Nature Biotechnology, and the British Medical Journal. He has appeared on many radio and television shows including 60 Minutes, Good Morning America, The Today Show, CBS This Morning, FOX news Sunday, and ABC World News and NPR. In addition to his scholarly work, he has published Opinion pieces in the Philadelphia Inquirer, the Chicago Tribune, the San Jose Mercury News, and the New Jersey Star Ledger.

Christine Von Raesfeld, Light Collective –
Christine Von Raesfeld is a research advocate and community engagement leader working at the intersection of health, data, and emerging technologies. As a person with lived experience of multiple rare and chronic conditions, she brings a patient-centered perspective to research, innovation, and healthcare systems.
Her work focuses on advancing participatory medicine through meaningful collaboration between patients, researchers, and institutions. She contributes to national and international initiatives including the NIH All of Us Research Program, the NIH HEAL Initiative, and advisory efforts with the Global Alliance for Genomics and Health (GA4GH) and BeginNGS. She also serves as a board member and community liaison for The Light Collective, where she co-developed a patient-led AI Rights framework.

Christine is actively engaged in patient-partnered research as a research collaborator and data contributor, sharing her own genomic and longitudinal multi-omic data through programs including Stanford's Humanwide initiative, the GENE 240 course, and the Research to the People program. Her work reflects a strong interest in precision medicine, including pharmacogenomics, and a commitment to more transparent, inclusive, and ethical models of data sharing.

She has participated in national discussions on healthcare and technology, including providing testimony before the California Health Committee on generative AI, and contributes to ongoing conversations around patient safety, trust, and data governance. Through her writing, speaking, and collaboration, she works to ensure that people with lived experience are recognized as essential partners in healthcare research and innovation.